Aspirin: Pharmacology and Clinical Applications
Author(s) -
Enma Verónica Paez Espinosa,
John P. Murad,
Fadi T. Khasawneh
Publication year - 2011
Publication title -
thrombosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.494
H-Index - 3
eISSN - 2090-1496
pISSN - 2090-1488
DOI - 10.1155/2012/173124
Subject(s) - medicine , aspirin , antithrombotic , atrial fibrillation , myocardial infarction , heparin , thrombosis , coronary artery disease , clopidogrel , intensive care medicine , cardiology , pharmacology
Antiplatelet therapy has been documented to reduce risks of cardiovascular disease after acute myocardial infarction, coronary artery bypass graft, and in chronic atrial fibrillation patients, amongst other risk factors. Conventional management of thrombosis-based disorders includes the use of heparin, oral anticoagulants, and the preferred antiplatelet agent aspirin. Interestingly, aspirin was not intended to be used as an antiplatelet agent; rather, after being repurposed, it has become one of the most widely prescribed antithrombotic drugs. To this end, there have been several milestones in the development of antiplatelet agents in the last few decades, such as adenosine diphosphate receptor inhibitors, phosphodiesterase inhibitors, and GPIIb/IIIa inhibitors. However, given some of the limitations of these therapies, aspirin continues to play a major role in the management of thrombotic and cardiovascular disorders and is expected to do so for years to come.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom